Serum soluble fas in patients with schistosomal cor pulmonale

Respiration

Volumn 70, Issue 6, 2003, Pages 574-578

  Salama, Mai ^a   El Kholy, Gamal ^a   Abd El Haleem, Soheir ^a   Elzamarany, Enas ^a   Freikha, Mohamed Abou ^a   Elwan, Nadia ^a   El Masry, Magdy ^a   Al Bacil, Amr ^a   Elhendy, Abdou ^b,c  

^a TANTA UNIVERSITY HOSPITAL   (Egypt)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Fas; Pulmonary hypertension; Schistosomal cor pulmonale

Indexed keywords

FAS LIGAND;

ADULT; APOPTOSIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COR PULMONALE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY ARTERY; SCHISTOSOMA; SCHISTOSOMIASIS; STATISTICAL SIGNIFICANCE;

ADULT; ANTIGENS, CD95; CASE-CONTROL STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY HEART DISEASE; SCHISTOSOMIASIS;

EID: 0942278979     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075201     Document Type: Article

References (27)

1. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF: The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001;22:405-418.
2. Cheng J, Zohon T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by soluble form of the Fas molecule. Science 1994;263: 1759-1762.
3. Thompson C: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267: 1456-1462.
4. Steller H: Mechanisms and genes of cellular suicide. Science 1995;267:1445-1449.
5. James T: Normal and abnormal consequences of apoptosis in the human heart: From postnatal morphogenesis to paroxysmal arrhythmia. Circulation 1994;90:556-573.
6. Bennett MR: Apoptosis in the cardiovascular system. Heart 2002;87:480-487.
7. Grodzicky T, Elkon KB: Apoptosis in rheumatic diseases. Am J Med 2000;108:73-82.
8. James TN: Apoptosis in cardiac disease (review). Am J Med 1999;107:606-620.
9. Bethlem EP, Schettino Gde P, Carvalho CR: Pulmonary schistosomiasis. Curr Opin Pulm Med 1997;3:361-365.
10. Morris W, Knauer CM: Cardiopulmonary manifestations of schistosomiasis (review). Semin Respir Infect 1997;12:159-170.
11. Andrade Z, Andrade S: Pathogenesis of schistosomal pulmonary arteritis. Am J Trop Med Hyg 1970;19:305-310.
12. Sadigursky M, Andrade ZA: Pulmonary changes in schistosomal cor pulmonale. Am J Trop Med Hyg 1982;31:779-784.
13. Rabinovitch M: Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 2001;22:433-449.
14. Jones P, Rabinovitch M: Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 1996;79:1131-1142.
15. Jones P, Cowan K, Rabinovitch M: Tenascin C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997;150:1349-1360.
16. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:2242-2244.
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
18. Yock PG, Popp RL: Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-662.
19. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E: Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6: 359-365.
20. Yue TL, Ohlstein EH, Ruffolo RR Jr: Apoptosis: A potential target for discovering novel therapies for cardiovascular diseases. Curr Opin Chem Biol 1999;3:474-480.
21. Thompson CB: Apoptosis in the pathogenesis and treatment of disease (review). Science 1995;267:1456-1462.
22. Naeije R, Barbera JA: Pulmonary hypertension associated with COPD. Crit Care 2001;5:286-289.
23. Majo J, Ghezzo H, Cosio MG: Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001;17:946-953.
24. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-1319.
25. Kasahara Y, Tuder RM, Cool CD, Voelkel NF: Expression of 15-lipoxygenase and evidence for apoptosis in the lungs from patients with COPD. Chest 2000;117(suppl 1):260S.
26. Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nomura M, Ohno A, Watanabe M, Sano H, Kumada H, Sawa T, Fujiwara H: An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998;92:993-999.
27. Takabatake N, Nakamura H, Inoue S, Terashi-ta K, Yuki H, Kato S, Yasumura S, Tomoike H: Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med 2000;94: 1215-1220.